{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T08:53:52Z","timestamp":1788512032072,"version":"build-2803163510"},"reference-count":72,"publisher":"MDPI AG","issue":"14","license":[{"start":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T00:00:00Z","timestamp":1752105600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"A Cure for Robert, Inc.","award":["1R01HD102545-01A1"],"award-info":[{"award-number":["1R01HD102545-01A1"]}]},{"name":"Morquio Foundations (A Cure for Robert, Inc., Angelo R. Cali &amp; Mary V. Cali Family Foundation, The Bennett Foundation), and Nemours Funds","award":["1R01HD102545-01A1"],"award-info":[{"award-number":["1R01HD102545-01A1"]}]},{"name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","award":["1R01HD102545-01A1"],"award-info":[{"award-number":["1R01HD102545-01A1"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Mucopolysaccharidosis IVA (MPS IVA) is a lysosomal storage disorder causing systemic skeletal dysplasia due to a deficiency of N-acetyl-galactosamine-6-sulfate sulfatase (GALNS) enzyme activity, leading to the impaired degradation and accumulation of glycosaminoglycans (GAGs), keratan sulfate (KS) and chondroitin-6-sulfate. While treatments such as enzyme replacement therapy (ERT) and hematopoietic stem cell transplantation (HSCT) are available, they have significant limitations regarding efficacy in skeletal tissues and long-term safety, highlighting the need for more effective therapies. We evaluated a novel gene therapy approach using a dual Integrase-deficient lentiviral vector (IDLV) to deliver an expression cassette that includes human GALNS cDNA and Cas9 sgRNA, targeting the upstream region of the mouse Galns initial codon. This approach leverages the endogenous promoter to drive transgene expression. We assessed in vitro transduction, editing, and functional correction in NIH3T3 and MPS IVA mouse fibroblasts. In vivo efficacy was successfully evaluated via the facial vein injection in MPS IVA newborn mice. In vitro, this IDLV platform demonstrated supraphysiological GALNS activity in cell lysate, resulting in the normalization of KS levels. In vivo direct IDLV platform in newborn MPS IVA mice led to sustained plasma GALNS activity, reduced plasma KS, and favorable biodistribution. Partial correction of heart and bone pathology was observed, with no vector toxicity and minimal antibody responses. This dual IDLV-CRISPR\/Cas9 approach effectively mediated targeted GALNS knock-in, yielding sustained enzyme activity, reduced KS storage, and partial pathological amelioration in MPS IVA mice. In conclusion, IDLVs represent an efficient, safe platform for delivering the CRISPR\/Cas9 gene editing system for MPS IVA.<\/jats:p>","DOI":"10.3390\/ijms26146616","type":"journal-article","created":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T12:46:33Z","timestamp":1752237993000},"page":"6616","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Integrase-Deficient Lentiviral Vector as a Platform for Efficient CRISPR\/Cas9-Mediated Gene Editing for Mucopolysaccharidosis IVA"],"prefix":"10.3390","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7511-6620","authenticated-orcid":false,"given":"Fnu","family":"Nidhi","sequence":"first","affiliation":[{"name":"Nemours Children\u2019s Health, Wilmington, DE 19803, USA"},{"name":"Faculty of Arts and Sciences, University of Delaware, Newark, DE 19716, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0673-2160","authenticated-orcid":false,"given":"Shunji","family":"Tomatsu","sequence":"additional","affiliation":[{"name":"Nemours Children\u2019s Health, Wilmington, DE 19803, USA"},{"name":"Department of Pediatrics, Graduate School of Medicine, Gifu University, Gifu 501-1193, Japan"},{"name":"Department of Pediatrics, Thomas Jefferson University, Philadelphia, PA 19107, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,7,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.ymgme.2013.04.002","article-title":"Review of clinical presentation and diagnosis of mucopolysaccharidosis IVA","volume":"110","author":"Hendriksz","year":"2013","journal-title":"Mol. Genet. Metab."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ymgme.2018.05.004","article-title":"Molecular genetics and metabolism, special edition: Diagnosis, diagnosis and prognosis of Mucopolysaccharidosis IVA","volume":"125","author":"Peracha","year":"2018","journal-title":"Mol. Genet. Metab."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Sawamoto, K., \u00c1lvarez Gonz\u00e1lez, J., Piechnik, M., Otero, F., Couce, M., Suzuki, Y., and Tomatsu, S. (2020). Mucopolysaccharidosis IVA: Diagnosis, Treatment, and Management. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21041517"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.ymgme.2016.11.007","article-title":"Mucopolysaccharidosis IVA and glycosaminoglycans","volume":"120","author":"Khan","year":"2017","journal-title":"Mol. Genet. Metab."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1002\/humu.20257","article-title":"Mutation and polymorphism spectrum of the GALNS gene in mucopolysaccharidosis IVA (Morquio A)","volume":"26","author":"Tomatsu","year":"2005","journal-title":"Hum. Mutat."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ymgme.2013.06.007","article-title":"Newborn screening and diagnosis of mucopolysaccharidoses","volume":"110","author":"Tomatsu","year":"2013","journal-title":"Mol. Genet. Metab."},{"key":"ref_7","first-page":"15","article-title":"Chondroitin 6-Sulfate as a Novel Biomarker for Mucopolysaccharidosis IVA and VII","volume":"16","author":"Shimada","year":"2014","journal-title":"JIMD Rep."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.matbio.2020.09.002","article-title":"Biglycan and chondroitin sulfate play pivotal roles in bone toughness via retaining bound water in bone mineral matrix","volume":"94","author":"Hua","year":"2020","journal-title":"Matrix Biol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1053\/sarh.2000.24874","article-title":"Biochemical basis of the pharmacologic action of chondroitin sulfates on the osteoarticular system","volume":"31","author":"Bali","year":"2001","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Jung, Y.-K., Park, H.-R., Cho, H.-J., Jang, J.-A., Lee, E.-J., Han, M.-S., Kim, G.-W., and Han, S. (2019). Degrading products of chondroitin sulfate can induce hypertrophy-like changes and MMP-13\/ADAMTS5 production in chondrocytes. Sci. Rep., 9.","DOI":"10.1038\/s41598-019-52358-4"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"108507","DOI":"10.1016\/j.ymgme.2024.108507","article-title":"Causes of death in mucopolysaccharidoses","volume":"142","author":"Rintz","year":"2024","journal-title":"Mol. Genet. Metab."},{"key":"ref_12","first-page":"7976780","article-title":"Tracheal Resection for Critical Airway Obstruction in Morquio A Syndrome","volume":"2023","author":"Frauenfelder","year":"2023","journal-title":"Case Rep. Pediatr."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Parini, R., and Deodato, F. (2020). Intravenous Enzyme Replacement Therapy in Mucopolysaccharidoses: Clinical Effectiveness and Limitations. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21082975"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/s13023-019-1074-9","article-title":"Recommendations for the management of MPS IVA: Systematic evidence- and consensus-based guidance","volume":"14","author":"Akyol","year":"2019","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e226","DOI":"10.1016\/j.bbmt.2019.02.012","article-title":"Hematopoietic Stem Cell Transplantation for Mucopolysaccharidoses: Past, Present, and Future","volume":"25","author":"Taylor","year":"2019","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e156","DOI":"10.1055\/s-0038-1667346","article-title":"Causal Therapies in Mucopolysaccharidoses: Enzyme Replacement Therapy","volume":"8","author":"Vartanyan","year":"2018","journal-title":"J. Child Sci."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s13052-018-0562-1","article-title":"Enzyme replacement therapy: Efficacy and limitations","volume":"44","author":"Concolino","year":"2018","journal-title":"Ital. J. Pediatr."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.2147\/DDDT.S68562","article-title":"Impact of enzyme replacement therapy and hematopoietic stem cell transplantation in patients with Morquio A syndrome","volume":"9","author":"Tomatsu","year":"2015","journal-title":"Drug Des. Devel. Ther."},{"key":"ref_19","first-page":"S71","article-title":"Evidence-based, expert-agreed recommendations for the management of patients with MPS IVA\/VI: Recommendations to replace the specific missing enzyme","volume":"126","author":"Hendriksz","year":"2019","journal-title":"Mol. Genet. Metab."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"101153","DOI":"10.1016\/j.omtm.2023.101153","article-title":"Iron oxide-coupled CRISPR-nCas9-based genome editing assessment in mucopolysaccharidosis IVA mice","volume":"31","author":"Leal","year":"2023","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/s41434-022-00344-3","article-title":"Efficient CRISPR\/Cas9 nickase-mediated genome editing in an in vitro model of mucopolysaccharidosis IVA","volume":"30","author":"Leal","year":"2022","journal-title":"Gene Ther."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/nmeth.3993","article-title":"A multifunctional AAV\u2013CRISPR\u2013Cas9 and its host response","volume":"13","author":"Chew","year":"2016","journal-title":"Nat. Methods"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/s41551-019-0431-2","article-title":"Immune-orthogonal orthologues of AAV capsids and of Cas9 circumvent the immune response to the administration of gene therapy","volume":"3","author":"Moreno","year":"2019","journal-title":"Nat. Biomed. Eng."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1016\/j.ymthe.2020.04.017","article-title":"AAV-CRISPR Gene Editing Is Negated by Pre-existing Immunity to Cas9","volume":"28","author":"Li","year":"2020","journal-title":"Mol. Ther."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1080\/10717544.2018.1474964","article-title":"Delivering CRISPR: A review of the challenges and approaches","volume":"25","author":"Lino","year":"2018","journal-title":"Drug Deliv."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Brault, J., Liu, T., Liu, S., Lawson, A., Choi, U., Kozhushko, N., Bzhilyanskaya, V., Pavel-Dinu, M., Meis, R.J., and Eckhaus, M.A. (2023). CRISPR-Cas9-AAV versus lentivector transduction for genome modification of X-linked severe combined immunodeficiency hematopoietic stem cells. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.1067417"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.omtm.2017.04.002","article-title":"Integrase-Deficient Lentiviral Vector as an All-in-One Platform for Highly Efficient CRISPR\/Cas9-Mediated Gene Editing","volume":"5","author":"Ortinski","year":"2017","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Lyu, M., Sun, Y., Yan, N., Chen, Q., Wang, X., Wei, Z., Zhang, Z., and Xu, K. (2023). Efficient CRISPR\/Cas9-mediated gene editing in mammalian cells by the novel selectable traffic light reporters. Int. J. Biol. Macromol., 243.","DOI":"10.1016\/j.ijbiomac.2023.124926"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/nbt.3198","article-title":"Increasing the efficiency of homology-directed repair for CRISPR-Cas9-induced precise gene editing in mammalian cells","volume":"33","author":"Chu","year":"2015","journal-title":"Nat. Biotechnol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.omtn.2018.08.007","article-title":"The IS2 Element Improves Transcription Efficiency of Integration-Deficient Lentiviral Vector Episomes","volume":"13","author":"Sanchez","year":"2018","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Cortijo-Guti\u00e9rrez, M., S\u00e1nchez-Hern\u00e1ndez, S., Trist\u00e1n-Manzano, M., Maldonado-P\u00e9rez, N., Lopez-Onieva, L., Real, P.J., Herrera, C., Marchal, J.A., Martin, F., and Benabdellah, K. (2021). Improved Functionality of Integration-Deficient Lentiviral Vectors (IDLVs) by the Inclusion of IS2 Protein Docks. Pharmaceutics, 13.","DOI":"10.3390\/pharmaceutics13081217"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/s41591-018-0326-x","article-title":"Identification of preexisting adaptive immunity to Cas9 proteins in humans","volume":"25","author":"Charlesworth","year":"2019","journal-title":"Nat. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/gt.2010.105","article-title":"Robust cardiomyocyte-specific gene expression following systemic injection of AAV: In vivo gene delivery follows a Poisson distribution","volume":"18","author":"Prasad","year":"2010","journal-title":"Gene Ther."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.ymgme.2012.05.005","article-title":"Enzyme replacement therapy (ERT) procedure for mucopolysaccharidosis type II (MPS II) by intraventricular administration (IVA) in murine MPS II","volume":"107","author":"Higuchi","year":"2012","journal-title":"Mol. Genet. Metab."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"931","DOI":"10.2174\/138920111795542615","article-title":"Rowan, D.; Smith, M.; Barrera, L.; Chinen, Y.; M. Thacker, M.; G. Mackenzie, W.; Suzuki, Y.; et al. Mucopolysaccharidosis Type IVA (Morquio A Disease): Clinical Review and Current Treatment: A Special Review","volume":"12","author":"Tomatsu","year":"2011","journal-title":"Curr. Pharm. Biotechnol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"3345","DOI":"10.1038\/s41467-023-38582-7","article-title":"Functional gene delivery to and across brain vasculature of systemic AAVs with endothelial-specific tropism in rodents and broad tropism in primates","volume":"14","author":"Chen","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"5343","DOI":"10.1038\/s41467-021-25697-y","article-title":"Treatment of skeletal and non-skeletal alterations of Mucopolysaccharidosis type IVA by AAV-mediated gene therapy","volume":"12","author":"Bertolin","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"101447","DOI":"10.1016\/j.omtm.2025.101447","article-title":"Evaluation of AAV vectors with tissue-specific or ubiquitous promoters in a mouse model of mucopolysaccharidosis type IVA","volume":"33","author":"Khan","year":"2025","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_39","first-page":"119","article-title":"Adeno-associated virus as a gene therapy vector: Vector development, production and clinical applications","volume":"99","author":"Grieger","year":"2005","journal-title":"Adv. Biochem. Eng. Biotechnol."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Weber, T. (2021). Anti-AAV Antibodies in AAV Gene Therapy: Current Challenges and Possible Solutions. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.658399"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1016\/j.stem.2022.09.001","article-title":"Choice of template delivery mitigates the genotoxic risk and adverse impact of editing in human hematopoietic stem cells","volume":"29","author":"Ferrari","year":"2022","journal-title":"Cell Stem Cell"},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Ago, Y., Rintz, E., Musini, K., Ma, Z., and Tomatsu, S. (2024). Molecular Mechanisms in Pathophysiology of Mucopolysaccharidosis and Prospects for Innovative Therapy. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25021113"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Rintz, E., Herre\u00f1o-Pach\u00f3n, A.M., Celik, B., Nidhi, F., Khan, S., Benincore-Fl\u00f3rez, E., and Tomatsu, S. (2023). Bone Growth Induction in Mucopolysaccharidosis IVA Mouse. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24129890"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1089\/hum.2024.096","article-title":"Adeno-Associated Virus Gene Transfer Ameliorates Progression of Skeletal Lesions in Mucopolysaccharidosis IVA Mice","volume":"35","author":"Sawamoto","year":"2024","journal-title":"Hum. Gene Ther."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.ymthe.2020.01.001","article-title":"Immune Responses to Viral Gene Therapy Vectors","volume":"28","author":"Shirley","year":"2020","journal-title":"Mol. Ther."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1089\/hum.2024.094","article-title":"Lentiviral Vector-Mediated Ex Vivo Hematopoietic Stem Cell Gene Therapy for Mucopolysaccharidosis IVA Murine Model","volume":"35","author":"Celik","year":"2024","journal-title":"Hum. Gene Ther."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1111\/brv.12718","article-title":"Humoral immune responses to <scp>AAV<\/scp> gene therapy in the ocular compartment","volume":"96","author":"Whitehead","year":"2021","journal-title":"Biol. Rev."},{"key":"ref_48","first-page":"4175","article-title":"Variability of adenovirus receptor density influences gene transfer efficiency and therapeutic response in head and neck cancer","volume":"5","author":"Li","year":"1999","journal-title":"Clin. Cancer Res."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Kurhaluk, N., and Tkaczenko, H. (2025). Recent Issues in the Development and Application of Targeted Therapies with Respect to Individual Animal Variability. Animals, 15.","DOI":"10.3390\/ani15030444"},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"CRamirez, J. (2019). Lentiviral Vectors Come of Age? Hurdles and Challenges in Scaling Up Manufacture. Systems Biology, IntechOpen.","DOI":"10.5772\/intechopen.81105"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1002\/1521-2254(200009\/10)2:5<308::AID-JGM131>3.0.CO;2-3","article-title":"Lentiviral vectors: Excellent tools for experimental gene transfer and promising candidates for gene therapy","volume":"2","author":"Vigna","year":"2000","journal-title":"J. Gene Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1097\/JOM.0000000000000879","article-title":"Risks Associated With Lentiviral Vector Exposures and Prevention Strategies","volume":"58","author":"Schlimgen","year":"2016","journal-title":"J. Occup. Environ. Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.ymthe.2006.03.026","article-title":"Designing Nonviral Vectors for Efficient Gene Transfer and Long-Term Gene Expression","volume":"14","author":"Jackson","year":"2006","journal-title":"Mol. Ther."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1038\/gt.2008.113","article-title":"Persistent episomal transgene expression in liver following delivery of a scaffold\/matrix attachment region containing non-viral vector","volume":"15","author":"Argyros","year":"2008","journal-title":"Gene Ther."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1182\/blood-2002-01-0219","article-title":"Development of virus vectors for gene therapy of \u03b2 chain hemoglobinopathies: Flanking with a chromatin insulator reduces \u03b3-globin gene silencing in vivo","volume":"100","author":"Emery","year":"2002","journal-title":"Blood"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/sj.gt.3301139","article-title":"Insulation from viral transcriptional regulatory elements improves inducible transgene expression from adenovirus vectors in vitro and in vivo","volume":"7","author":"Steinwaerder","year":"2000","journal-title":"Gene Ther."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Duverg\u00e9, A., and Negroni, M. (2020). Pseudotyping Lentiviral Vectors: When the Clothes Make the Virus. Viruses, 12.","DOI":"10.3390\/v12111311"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"387","DOI":"10.2174\/1566523054546224","article-title":"Altering the Tropism of Lentiviral Vectors through Pseudotyping","volume":"5","author":"Cronin","year":"2005","journal-title":"Curr. Gene Ther."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Wang, Y., and Shao, W. (2023). Innate Immune Response to Viral Vectors in Gene Therapy. Viruses, 15.","DOI":"10.3390\/v15091801"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1038\/nbt.3190","article-title":"Increasing the efficiency of precise genome editing with CRISPR-Cas9 by inhibition of nonhomologous end joining","volume":"33","author":"Maruyama","year":"2015","journal-title":"Nat. Biotechnol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"20","DOI":"10.12703\/r\/9-20","article-title":"CRISPR-based strategies for targeted transgene knock-in and gene correction","volume":"9","author":"Lau","year":"2020","journal-title":"Fac. Rev."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1038\/s41467-018-03475-7","article-title":"CtIP fusion to Cas9 enhances transgene integration by homology-dependent repair","volume":"9","author":"Charpentier","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1038\/s41467-018-04609-7","article-title":"Targeting repair pathways with small molecules increases precise genome editing in pluripotent stem cells","volume":"9","author":"Riesenberg","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/nature17946","article-title":"Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage","volume":"533","author":"Komor","year":"2016","journal-title":"Nature"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/s41586-019-1711-4","article-title":"Search-and-replace genome editing without double-strand breaks or donor DNA","volume":"576","author":"Anzalone","year":"2019","journal-title":"Nature"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1038\/nbt1353","article-title":"Gene editing in human stem cells using zinc finger nucleases and integrase-defective lentiviral vector delivery","volume":"25","author":"Lombardo","year":"2007","journal-title":"Nat. Biotechnol."},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Herreno-Pach\u00f3n, A.M., Leal, A.F., Khan, S., Alm\u00e9ciga-D\u00edaz, C.J., and Tomatsu, S. (2025). CRISPR\/nCas9-Edited CD34+ Cells Rescue Mucopolysaccharidosis IVA Fibroblasts Phenotype. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26094334"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"4045","DOI":"10.1038\/s41467-019-11962-8","article-title":"Human genome-edited hematopoietic stem cells phenotypically correct Mucopolysaccharidosis type I","volume":"10","author":"Scharenberg","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1038\/s41467-022-28762-2","article-title":"A systematic review and meta-analysis of gene therapy with hematopoietic stem and progenitor cells for monogenic disorders","volume":"13","author":"Tucci","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_70","first-page":"e05113","article-title":"Clarification of some aspects related to genotoxicity assessment","volume":"15","author":"Hardy","year":"2017","journal-title":"EFSA J."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/978-1-0716-2946-8_1","article-title":"Detection of Glycosaminoglycans in Biological Specimens","volume":"2619","author":"Khan","year":"2023","journal-title":"Methods Mol. Biol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"3349","DOI":"10.1093\/hmg\/ddg366","article-title":"Mouse model of N-acetylgalactosamine-6-sulfate sulfatase deficiency (Galns\u2212\/\u2212) produced by targeted disruption of the gene defective in Morquio A disease","volume":"12","author":"Tomatsu","year":"2003","journal-title":"Hum. Mol. Genet."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/14\/6616\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:07:48Z","timestamp":1760033268000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/14\/6616"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,10]]},"references-count":72,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["ijms26146616"],"URL":"https:\/\/doi.org\/10.3390\/ijms26146616","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,10]]}}}